TVRDHIGH SIGNALMANAGEMENT10-K

TVRD underwent a transformative reverse merger with Cara Therapeutics in April 2025, fundamentally changing the company's structure and operations.

The merger between Legacy Tvardi and Cara Therapeutics represents a complete corporate reorganization, with Cara acquiring Tvardi and then adopting the Tvardi name. This type of reverse merger typically signals a strategic pivot or consolidation play, potentially aimed at combining complementary assets or achieving operational synergies. The transaction fundamentally alters the investment thesis for existing shareholders.

Comparing 2026-03-31 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

The financial statements reflect dramatic improvements in operating performance, with net losses and operating losses both substantially reduced year-over-year. R&D expenses declined meaningfully by 45%, while operating cash flow burn improved notably. However, the balance sheet shows significant deleveraging with total liabilities dropping 77% and cash reserves declining 45% to $20.7M, suggesting the merger involved substantial restructuring and cash utilization to reduce debt burdens.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-85.3%
$2.8M→$407K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Total Liabilities
Balance Sheet
-77%
$48.4M→$11.1M

Liabilities reduced 77% — deleveraging improves balance sheet strength and financial flexibility.

Net Income
P&L
+74.3%
-$70.9M→-$18.2M

Net income grew 74.3% — bottom-line growth signals improving overall business health.

Inventory
Balance Sheet
-68.1%
$2.8M→$900K

Inventory drawn down 68.1% — strong sell-through or deliberate destocking; watch for supply constraints.

Operating Cash Flow
Cash Flow
+61.4%
-$60.9M→-$23.5M

Operating cash flow surged 61.4% — exceptional cash generation, highest quality earnings signal.

Capital Expenditure
Cash Flow
-56%
$2.4M→$1.0M

Capex reduced 56% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Income
P&L
+54.2%
-$58.4M→-$26.7M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Cash & Equivalents
Balance Sheet
-45.3%
$37.9M→$20.7M

Cash declined 45.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

R&D Expense
P&L
-45.1%
$32.8M→$18.0M

R&D spending cut 45.1% — could signal cost discipline or concerning reduction in innovation investment.

Current Assets
Balance Sheet
-28%
$43.8M→$31.5M

Current assets declined 28% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-11
ADDED
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Certain Relationships and Related Transactions, and Director Independence.
(Legacy Tvardi) entered into an agreement and plan of merger and reorganization (the Merger Agreement) with Cara Therapeutics, Inc.
(Cara) and CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of Cara (Merger Sub), pursuant to which Merger Sub merged with and into Legacy Tvardi, with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of Cara (such transaction, the Merger).
Upon the closing of the Merger on April 15, 2025 (the Closing Date), Cara changed its corporate name to Tvardi Therapeutics, Inc.
and Legacy Tvardi s business continued as the business of Tvardi Therapeutics, Inc.
Pursuant to the Merger Agreement, on the Closing Date, (i) Cara effected a 1-for-3 reverse stock split of its common stock (the Reverse Stock Split), (ii) Cara increased its authorized shares of common stock to 150,000,000, (iii) Merger Sub was merged with and into Legacy Tvardi and Legacy Tvardi became a wholly owned subsidiary of Cara, and (iv) Cara changed its name to Tvardi Therapeutics, Inc .
The consolidated financial statements included in this Annual Report on Form 10-K include historical information of Tvardi Therapeutics, Inc., including as of and for the years ended December 31, 2025 and 2024, unless otherwise indicated or as the context otherwise requires.
In addition, except where otherwise indicated or the context otherwise requires, the information in this Annual Report on Form 10-K as of and for the periods prior to the effective time of the Merger gives effect to the Merger.
REMOVED
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities .
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters .
Certain Relationships and Related Transactions, and Director Independence .
Ltd., or Maruishi, and Chong Kun Dang Pharmaceutical Corp., or CKDP, as well as sub-licensees, including Winhealth Pharma and Kissei Pharmaceutical Co.
Ltd., or Kissei, and our ability to maintain such collaborations.
We qualify all of our forward-looking statements by these cautionary statements.
Risk Factors Summary Investing in our common stock involves a high degree of risk because our business is subject to numerous risks and uncertainties, as more fully described below.
The principal factors and uncertainties that make investing in our common stock risky include, among others: Failure to complete, or delays in completing, the Merger with Tvardi could materially and adversely affect our results of operations, business, financial results and/or stock price.
Failure to complete the Merger may result in Cara or Tvardi paying a termination fee to the other party and could harm the common stock price of Cara.
The Merger may be completed even though material adverse changes may result from the announcement of the Merger, industry-wide changes and/or other causes.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →